Primecap Management Co. CA Has $66.12 Million Stake in Immunocore Holdings plc (NASDAQ:IMCR)

Primecap Management Co. CA boosted its position in Immunocore Holdings plc (NASDAQ:IMCR) by 3,841.6% in the second quarter, Holdings Channel.com reports. The firm owned 1,951,070 shares of the company’s stock after purchasing an additional 1,901,570 shares during the quarter. Primecap Management Co. CA’s holdings in Immunocore were worth $66,122,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Renaissance Technologies LLC grew its holdings in shares of Immunocore by 14.5% during the second quarter. Renaissance Technologies LLC now owns 646,920 shares of the company’s stock worth $21,924,000 after purchasing an additional 82,120 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in Immunocore by 25.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 390,565 shares of the company’s stock worth $13,236,000 after buying an additional 79,444 shares during the period. Envestnet Asset Management Inc. grew its holdings in Immunocore by 0.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 70,571 shares of the company’s stock worth $2,392,000 after acquiring an additional 606 shares during the last quarter. Candriam S.C.A. increased its position in Immunocore by 65.8% in the 2nd quarter. Candriam S.C.A. now owns 313,423 shares of the company’s stock valued at $10,621,000 after acquiring an additional 124,417 shares during the period. Finally, TD Asset Management Inc raised its stake in shares of Immunocore by 23.2% during the second quarter. TD Asset Management Inc now owns 264,896 shares of the company’s stock valued at $8,977,000 after acquiring an additional 49,882 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IMCR. Barclays reduced their price objective on shares of Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. JPMorgan Chase & Co. reduced their price target on Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 10th. Needham & Company LLC lowered their price objective on Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a research report on Tuesday. Oppenheimer reaffirmed an “outperform” rating and issued a $89.00 price objective (up from $87.00) on shares of Immunocore in a research note on Friday, August 9th. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $80.40.

Immunocore Trading Up 2.7 %

NASDAQ IMCR opened at $33.90 on Wednesday. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. Immunocore Holdings plc has a 52 week low of $32.37 and a 52 week high of $76.98. The business has a 50 day moving average price of $37.14 and a 200-day moving average price of $46.90. The company has a market cap of $1.70 billion, a price-to-earnings ratio of -27.79 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.25. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The business had revenue of $75.40 million during the quarter, compared to analyst estimates of $74.58 million. During the same quarter in the previous year, the business posted ($0.37) EPS. Immunocore’s quarterly revenue was up 26.2% on a year-over-year basis. As a group, equities analysts expect that Immunocore Holdings plc will post -1.79 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.